Depression News and Research

Latest Depression News and Research

FDA ADAC recommends approval of Gilead’s Truvada for HIV

Gilead Sciences, Inc. today announced that the Antiviral Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) has voted to support approval of once-daily oral Truvada(emtricitabine and tenofovir disoproxil fumarate) to reduce the risk of HIV-1 infection among uninfected adults, an HIV prevention strategy called pre-exposure prophylaxis or PrEP.

11 May 2012

Checking for specific genetic variants can help identify women at high risk of PND

Researchers at Warwick Medical School have discovered a way of identifying which women are most at risk of postnatal depression (PND) by checking for specific genetic variants.

10 May 2012

Newly diagnosed schizophrenia patients continue to use oral Abilify as first-line therapy

BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that analysis of U.S. longitudinal patient-level claims data reveals the use of Bristol-Myers Squibb's oral Abilify as a first-line therapy for newly diagnosed schizophrenia patients continues to grow.

10 May 2012

Genes determine brain size: Global brain study

In the world's largest study of the human brain, involving more than 200 scientists worldwide, researchers have found that genes that affect brain size may play a part in intelligence and memory function. The study was put together by combining brain scans and genetic data from 21,000 people worldwide.

10 May 2012

Sunovion announces results from LATUDA open-label study for schizophrenia

Sunovion Pharmaceuticals Inc. today announced results from an open-label study that switched clinically stable, but symptomatic adult outpatients with schizophrenia from other antipsychotic agents to LATUDA.

10 May 2012

Grade 12 researcher wins top honors at 2012 Sanofi BioGENEius Challenge Canada

An Ontario girl, 16, who invented a disease-fighting, anti-aging compound using nano-particles from trees, won top national honours today in the 2012 Sanofi BioGENEius Challenge Canada.

9 May 2012

Non-drug therapy with NeuroStar TMS improves depression symptoms and QOL

New data released today at the annual meeting of the American Psychiatric Association show that patients with unipolar, non-psychotic Major Depressive Disorder (MDD) receiving transcranial magnetic stimulation (TMS) with NeuroStar TMS Therapy achieved significant improvements in both depression symptoms and in quality of life measurements.

9 May 2012

Results reported for clinical trial for the treatment of depression using external trigeminal nerve stimulation

Earlier today, at the American Psychiatric Association Annual Meeting in Philadelphia, Dr. Ian Cook, Principal Investigator and Professor of Psychiatry at UCLA, and a Senior Medical Advisor to NeuroSigma, Inc., presented the results of a Phase Ib open-label clinical trial that studied the effects of eTNS™ on depressive symptoms in Major Depressive Disorder (MDD) as an adjunct to pharmacotherapy. Results from the 17-question Hamilton Depression Rating Scale (HDRS-17), a clinician-rated scale, showed a 50.0% reduction in depression and the Beck Depression Inventory (BDI), a self-reported scale, showed a 58.0% reduction in scores. Both scales achieved statistical significance. In the trial, subjects placed stimulating eTNS™ electrodes on their foreheads for 8 hours each night and their depression was measured every two weeks using recognized standard tests. eTNS was well tolerated and no serious adverse events occurred during the 8-week treatment period.

9 May 2012

Higher levels of income inequality in the U.S. lead to more deaths

A new study provides the best evidence to date that higher levels of income inequality in the United States actually lead to more deaths in the country over a period of years.

9 May 2012

Two studies suggest long-term value of Deplin in treating MDD

Two studies presented this week at the 164th Annual Meeting of the American Psychiatric Association suggest the long-term value of Deplin (L-methylfolate 15mg) in treating major depressive disorder (MDD) and describe subsets of patients who may benefit more robustly from this medical food.

9 May 2012

eTNS therapy can impact symptoms in pharmacoresistant major depression

9 May 2012

Caring for carers

According to a new poll, there are hundreds of thousands of unpaid carers in Scotland who are suffering from mental health problems and struggling to keep their jobs.

8 May 2012

Ritalin use in ADHD rises four-fold over a decade

According to latest figures prescriptions for Ritalin for attention deficit hyperactivity disorder (ADHD) have quadrupled in a decade. This has raised concerns that it is being given to children at the expense of alternative treatments and without appreciation of long-term effects.

8 May 2012

New analysis on why some soldiers never seek PTSD care

U.S. Army researcher Maj. Gary H. Wynn, M.D., shared new analysis on why some Soldiers suffering from combat-related post-traumatic stress disorder (PTSD) never seek care or drop out of treatment early during a presentation today at the American Psychiatric Association's annual meeting. His presentation, "Epidemiology of Combat-Related PTSD in U.S. Service Members: Lessons Learned," also described the approaches the Army is using to address this issue and improve overall patient outcomes.

8 May 2012

Rare form of dementia eats away at personality and language

Michael French suffered from a rare form of dementia. It made him do unwise things like throwing away tax documents, getting a ticket for trying to pass an ambulance and buying stock in companies that were obviously in trouble. He seemed withdrawn and no longer spoke to his wife over dinner. He also lost his job at the consulting firm. This happened in 2006. His wife found he had changed suddenly from the smart, good-natured, hardworking man and was considering divorce when his ailment came into the picture.

8 May 2012

Cigna encourages new mothers to get screened for prenatal and postpartum depression

A mother's emotional health is as important as her physical health during pregnancy and after delivery. That's why, during May, Maternal Depression Awareness Month, Cigna (NYSE: CI) is encouraging soon-to-be and new mothers to get screened and understand the symptoms of prenatal and postpartum depression.

8 May 2012

DBS may offer hope for patients with mild Alzheimer's

A study on a handful of people with suspected mild Alzheimer's disease (AD) suggests that a device that sends continuous electrical impulses to specific "memory" regions of the brain appears to increase neuronal activity. Results of the study using deep brain stimulation, a therapy already used in some patients with Parkinson's disease and depression, may offer hope for at least some with AD, an intractable disease with no cure.

8 May 2012

Otsuka announces results from aripiprazole Phase 3 trial on schizophrenia

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S today announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.

8 May 2012

Health Canada announces labelling update for Cipralex

Health Canada is informing Canadians of a labelling update for the prescription drug Cipralex (the brand name of the drug escitalopram) regarding a dose-related risk of abnormal heart rhythms. Cipralex is used to treat depression and belongs to a family of drugs known as Selective Serotonin Reuptake Inhibitors (SSRIs).

7 May 2012

Galleon GAL-021 safe and well-tolerated in Phase I respiratory depression clinical study

Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing disorders, today announced that its investigational drug GAL-021 appeared to be safe and well-tolerated and demonstrated dose-proportional pharmacokinetic effects on respiration in a Phase I clinical study of 30 healthy adults.

7 May 2012